





























参考图片
Expression of IFN-γ by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 h with PMA (50 ng/ml; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml; Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. 555334), fixed, permeabilized, and subsequently stained with 20 µl of PE Mouse Anti-Human IFN-γ (Cat. No. 559327/554701; left panel). To demonstrate specificity of staining, binding by the PE-B27 antibody was blocked by preincubation of fixed/permeabilized cells with Purified Mouse Anti-Human IFN-γ (5 µg; Cat. No. 554699/550011; right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabeled antibody blocking control.
Expression of IFN-γ by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 h with PMA (50 ng/ml; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml; Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. 555334), fixed, permeabilized, and subsequently stained with 20 µl of PE Mouse Anti-Human IFN-γ (Cat. No. 559327/554701; left panel). To demonstrate specificity of staining, binding by the PE-B27 antibody was blocked by preincubation of fixed/permeabilized cells with Purified Mouse Anti-Human IFN-γ (5 µg; Cat. No. 554699/550011; right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabeled antibody blocking control.